Vanguard Group Inc Solid Biosciences Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.51 - $7.56 $381,542 - $5.66 Million	748,123 Added 28.87%	3,339,156 $1.56 Million
Q2 2022 Aug 12, 2022	BUY	$0.43 - $1.24 $204,607 - $590,031	475,832 Added 22.5%	2,591,033 $1.6 Million
Q1 2022 May 13, 2022	SELL	$0.74 - $1.79 $342,733 - $829,043	-463,153 Reduced 17.96%	2,115,201 $2.54 Million
Q4 2021 Feb 14, 2022	SELL	$1.69 - $2.46 $355,298 - $517,180	-210,236 Reduced 7.54%	2,578,354 $4.51 Million
Q3 2021 Nov 12, 2021	BUY	$2.38 - $3.77 $61,432 - $97,311	25,812 Added 0.93%	2,788,590 $6.67 Million
Q2 2021 Aug 13, 2021	BUY	$3.49 - $5.51 $9.64 Million - $15.2 Million	2,762,778 New	2,762,778 $10.1 Million

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $29.8M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.